(2-chloropyrimidin-4-yl)cyclopropylmethylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (2-chloropyrimidin-4-yl)cyclopropylmethylamine
• 英文别名: 4-Cyclopropylmethylamino-2-chlorpyrimidin；2-chloro-4-(cyclopropylmethyl-amino)-pyrimidine；2-chloro-N-(cyclopropylmethyl)pyrimidin-4-amine
• 化学式: C₈H₁₀ClN₃
• 分子量: 183.64
• InChiKey: KPUULAQIYDLBOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(Boc-氨甲基)苯硼酸 、 (2-chloropyrimidin-4-yl)cyclopropylmethylamine 在 四(三苯基膦)钯 potassium carbonate 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 1.5h， 以20%的产率得到4-[4-(cyclopropylmethyl-amino)-pyrimidin-2-yl]-N-(tert-butoxycarbonyl)-benzylamine
  参考文献：
  名称：

  WO2007/28083

  摘要：

  公开号：
• 作为产物：
  描述：

  2,4-二氯嘧啶 、 环丙基甲胺 在 N,N-二异丙基乙胺 作用下， 以 异丙醇 为溶剂， 反应 0.25h， 以65%的产率得到(2-chloropyrimidin-4-yl)cyclopropylmethylamine
  参考文献：
  名称：

  WO2007/28083

  摘要：

  公开号：

文献信息

• 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists
  申请人：Briner Karin

  公开号：US20080269196A1

  公开（公告）日：2008-10-30

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.

  本发明提供了式（I）的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环化合物，作为选择性5-HT2c受体激动剂，用于治疗与5-HT2c相关的疾病，包括肥胖、强迫症/强迫性障碍、抑郁症和焦虑症，其中，R6为—NR10R11，其中R10为取代的苯基烷基或取代的吡啶基烷基，其他取代基如说明书所定义。
• 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
  申请人：BRINER Karin

  公开号：US20110269745A1

  公开（公告）日：2011-11-03

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.

  本发明提供了6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环化合物，其化学式为(I)，作为选择性5-HT2c受体激动剂，用于治疗5-HT2c相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症，其中，R6是—NR10R11，其中R10是取代的苯基烷基或取代的吡啶基烷基，其他取代基如规范中所定义。
• 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
  申请人：Briner Karen

  公开号：US08680091B2

  公开（公告）日：2014-03-25

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.

  本发明提供了式（I）的6-取代2,3,4,5-四氢-1H-苯并[d]氮杂环化合物作为选择性5-HT2c受体激动剂，用于治疗5-HT2c相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症，其中，R6为-NR10R11，其中R10为取代的苯基烷基或取代的吡啶基烷基，其他取代基如规范中定义。
• Substituted Azaheterocycles for the Treatment of Cancer
  申请人：Heinrich Timo

  公开号：US20140221366A1

  公开（公告）日：2014-08-07

  The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.

  本发明提供了一种根据式（I）提供的新型取代的杂氮杂环化合物，其制备和用于治疗过度增殖性疾病，如癌症。
• Amide-based inhibitors of p38α MAP kinase. Part 2: Design, synthesis and SAR of potent N-pyrimidyl amides
  作者：Richland Tester、Xuefei Tan、Gregory R. Luedtke、Imad Nashashibi、Kurt Schinzel、Weiling Liang、Joon Jung、Sundeep Dugar、Albert Liclican、Jocelyn Tabora、Daniel E. Levy、Steven Do

  DOI：10.1016/j.bmcl.2010.02.090

  日期：2010.4

  Optimization of a tri-substituted N-pyridyl amide led to the discovery of a new class of potent N-pyrimidyl amide based p38 alpha MAP kinase inhibitors. Initial SAR studies led to the identification of 5-dihydrofuran as an optimal hydrophobic group. Additional side chain modi. cations resulted in the introduction of hydrogen bond interactions. Through extensive SAR studies, analogs bearing free amino groups and alternatives to the parent (S)-alpha-methyl benzyl moiety were identified. These compounds exhibited improved cellular activities and maintained balance between p38a and CYP3A4 inhibition. (C) 2010 Elsevier Ltd. All rights reserved.